Skip to main content

REVIEW article

Front. Oncol.
Sec. Neuro-Oncology and Neurosurgical Oncology
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1454370
This article is part of the Research Topic Advances in Brain Tumor Therapy View all 5 articles

New Orleans, LA 70112 Editor, Frontiers in Oncology, for MS. ID# 145370R1 Re: The Transformative Potential of a mRNA-based Vaccine for Glioblastoma…

Provisionally accepted
Iulia Tapescu Iulia Tapescu 1Peter J. Madsen Peter J. Madsen 2Pedro Lowenstein Pedro Lowenstein 3Maria G. Castro Maria G. Castro 3Stephen Bagley Stephen Bagley 4Yi Fan Yi Fan 5Steven Brem Steven Brem 6,7*
  • 1 Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • 2 Division of Neurosurgery, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
  • 3 Department of Neurosurgery, School of Medicine, Michigan Medicine, University of Michigan, Ann Arbor, Michigan, United States
  • 4 Division of Hematology and Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • 5 Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • 6 University of Pennsylvania, Philadelphia, United States
  • 7 Department of Neurosurgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States

The final, formatted version of the article will be published soon.

    On behalf of the co-authors, we are grateful to you and the Reviewers #1 and #2 for their thoughtful and favorable review of our .ms, "The Transformative Potential of a mRNA-based Vaccine for Glioblastoma and Human Cancer: Technological Advances and Translation to Clinical Trials." Please find attached the revised .ms, Front Oncol #145370R1, using the tracking mode of MS Word. We respond to each of the suggestions (summarized below), using blue font (below).RESPONSE TO REVIEWER #1: mRNA is a highly versatile and powerful tool in the realm of biotechnology. This manuscript endeavors to provide a comprehensive understanding of mRNA vaccines for glioblastoma. Structured logically and comprehensively, it encompasses the latest knowledge on the design of mRNA vaccines, delivery systems, and their application in treating human cancer. Moreover, it delves into the future prospects of mRNA vaccines in depth. Prior to publication, however, the following revisions are recommended:Initial recommendation to the Editor: Minor revision is required.We are grateful for the favorable review and the constructive comments.1. Consistency in terminology is crucial. To enhance clarity, the authors should opt for a single term, either "mRNA vaccine" or "mRNA-based vaccine," and use it consistently throughout the manuscript.Thank you for bringing this ambiguity to our attention. Although the terms, mRNA vaccine and mRNA-based vaccines have been used interchangeably (see Gote V et al., A comprehensive review of mRNA vaccines.

    Keywords: brain tumor, Clinical Trial, Glioma, Glioblastoma, Immunotherapy, immuno-oncology, mRNA, Vaccine

    Received: 25 Jun 2024; Accepted: 09 Sep 2024.

    Copyright: © 2024 Tapescu, Madsen, Lowenstein, Castro, Bagley, Fan and Brem. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Steven Brem, University of Pennsylvania, Philadelphia, United States

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.